{
  "meta": {
    "id": "test37",
    "title": "Mid Day Module (Medicine-8) - 2024-12-20",
    "category": "Subject Wise / Mixed"
  },
  "questions": [
    {
      "text": "In a healthy adult male, the average daily iron absorption from dietary sources is approximately:",
      "options": [
        {
          "label": "A",
          "text": "0.5 mg",
          "correct": false
        },
        {
          "label": "B",
          "text": "1 mg",
          "correct": true
        },
        {
          "label": "C",
          "text": "1.4 mg",
          "correct": false
        },
        {
          "label": "D",
          "text": "2 mg",
          "correct": false
        }
      ],
      "correct_answer": "B. 1 mg",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) 1 mg</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "5bdc818d",
      "audio": ""
    },
    {
      "text": "Which of the following substances can IMPAIR the absorption of iron supplements?",
      "options": [
        {
          "label": "A",
          "text": "Ascorbic acid",
          "correct": false
        },
        {
          "label": "B",
          "text": "Orange juice",
          "correct": false
        },
        {
          "label": "C",
          "text": "Meat",
          "correct": false
        },
        {
          "label": "D",
          "text": "Antacids",
          "correct": true
        }
      ],
      "correct_answer": "D. Antacids",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Antacids</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option (A, B, C): Vitamin C (in ascorbic acid and orange juice) and meat can all improve iron absorption.</li><li>\u2022 Option (A, B, C):</li><li>\u2022 ascorbic acid</li><li>\u2022 orange juice)</li><li>\u2022 meat</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Patients taking iron supplements should avoid taking antacids concurrently, as this can reduce absorption.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ebc9e692",
      "audio": ""
    },
    {
      "text": "A patient with iron deficiency anemia is started on oral iron supplementation. When would you expect to see the PEAK reticulocyte response, indicating that the bone marrow is actively producing new red blood cells?",
      "options": [
        {
          "label": "A",
          "text": "Within 24-48 hours of starting therapy",
          "correct": false
        },
        {
          "label": "B",
          "text": "3-4 days after starting therapy",
          "correct": false
        },
        {
          "label": "C",
          "text": "7-10 days after starting therapy",
          "correct": true
        },
        {
          "label": "D",
          "text": "14-21 days after starting therapy",
          "correct": false
        }
      ],
      "correct_answer": "C. 7-10 days after starting therapy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) 7-10 days after starting therapy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Within 24-48 hours of starting therapy: This is too soon to expect a peak response. It takes several days for the bone marrow to ramp up red blood cell production.</li><li>\u2022 Option A.</li><li>\u2022 Within 24-48 hours of starting therapy:</li><li>\u2022 Option B. 3-4 days after starting therapy: While the reticulocyte count may start to rise within 3-4 days, the peak response is typically later.</li><li>\u2022 Option B. 3-4 days after starting therapy:</li><li>\u2022 Option D. 14-21 days after starting therapy: This is too late for the peak response. If there's no significant increase by this time, it could suggest a lack of response to therapy or an alternative diagnosis.</li><li>\u2022 Option D. 14-21 days after starting therapy:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The reticulocyte count is a valuable tool for monitoring the response to iron therapy in iron deficiency anemia. An increase in reticulocytes within 4-7 days and a peak response at 7-10 days are expected findings, indicating that the treatment is effective.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a80dca6",
      "audio": ""
    },
    {
      "text": "Which of the following alpha-globin gene arrangements is MOST likely to be associated with Hemoglobin H (HbH) disease?",
      "options": [
        {
          "label": "A",
          "text": "\u03b1\u03b1/\u03b1\u03b1",
          "correct": false
        },
        {
          "label": "B",
          "text": "-\u03b1/\u03b1\u03b1",
          "correct": false
        },
        {
          "label": "C",
          "text": "--/\u03b1\u03b1",
          "correct": false
        },
        {
          "label": "D",
          "text": "--/-\u03b1",
          "correct": true
        }
      ],
      "correct_answer": "D. --/-\u03b1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) --/-\u03b1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. \u03b1\u03b1/\u03b1\u03b1: \u03b1-thal. With Myelodysplasia - Mutations in ATRX ; striking male predominance. Hematologic findings of HbH disease.</li><li>\u2022 Option A. \u03b1\u03b1/\u03b1\u03b1:</li><li>\u2022 Option B. -\u03b1/\u03b1\u03b1: Represents the silent carrier state of alpha-thalassemia, with only one alpha-globin gene deleted. It typically doesn't cause significant clinical symptoms.</li><li>\u2022 Option B.</li><li>\u2022 -\u03b1/\u03b1\u03b1:</li><li>\u2022 Option C. --/\u03b1\u03b1: Represents alpha-thalassemia trait, where two alpha-globin genes are deleted. This condition can lead to mild anemia but is not associated with HbH disease.</li><li>\u2022 Option C.</li><li>\u2022 --/\u03b1\u03b1:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The specific arrangement and number of alpha-globin gene deletions determine the severity of alpha-thalassemia. HbH disease, a moderate form of the condition, is caused by the deletion or inactivation of three out of four alpha-globin genes, represented by the genotype --/-\u03b1 (other gene arrangement: \u03b1 T \u03b1/- -, \u03b1 T \u03b1/\u03b1 T \u03b1)</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c051cf5a",
      "audio": ""
    },
    {
      "text": "A 35-year-old woman with a history of mild anemia on routine blood work presents for a follow-up appointment. She reports good energy levels and denies any recent illnesses or blood loss. Her physical examination is unremarkable. A peripheral blood smear is shown in the image. Which of the following hematological conditions is MOST likely represented in this blood smear?",
      "options": [
        {
          "label": "A",
          "text": "Iron deficiency anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Vitamin B12 deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Sickle cell anemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Beta-thalassemia intermedia",
          "correct": true
        }
      ],
      "correct_answer": "D. Beta-thalassemia intermedia",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/screenshot-2024-07-31-124914.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Beta-thalassemia intermedia</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Iron deficiency anemia: While also microcytic and hypochromic, it usually does not exhibit target cells or the degree of poikilocytosis seen here.</li><li>\u2022 Option A. Iron deficiency anemia:</li><li>\u2022 Option B. Vitamin B12 deficiency: Causes macrocytic (large red blood cell) anemia, not microcytic.</li><li>\u2022 Option B. Vitamin B12 deficiency:</li><li>\u2022 Option C. Sickle cell anemia: Characterized by sickle-shaped red blood cells, which are not present in this image.</li><li>\u2022 Option C. Sickle cell anemia:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The presence of target cells, anisocytosis, poikilocytosis, hypochromia and microcytosis in a blood smear strongly suggests beta-thalassemia intermedia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "715e4fef",
      "audio": ""
    },
    {
      "text": "A patient presents with anemia and acrocyanosis that worsens in cold weather. Which of the following laboratory findings is most consistent with cold agglutinin syndrome (CAS)?",
      "options": [
        {
          "label": "A",
          "text": "Positive direct antiglobulin test (DAT) with anti-IgG specificity",
          "correct": false
        },
        {
          "label": "B",
          "text": "Positive DAT with anti-C3d specificity",
          "correct": false
        },
        {
          "label": "C",
          "text": "Positive DAT with anti-IgM specificity",
          "correct": true
        },
        {
          "label": "D",
          "text": "Negative DAT",
          "correct": false
        }
      ],
      "correct_answer": "C. Positive DAT with anti-IgM specificity",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Positive DAT with anti-IgM specificity</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Positive direct antiglobulin test (DAT) with anti-IgG specificity and Option B. Positive DAT with anti-C3d specificity are more commonly associated with WAIHA.</li><li>\u2022 Option A. Positive direct antiglobulin test (DAT) with anti-IgG specificity</li><li>\u2022 Option</li><li>\u2022 B. Positive DAT with anti-C3d specificity</li><li>\u2022 Option D. Negative DAT : A negative DAT would not be expected in a patient with autoimmune hemolytic anemia.</li><li>\u2022 Option D.</li><li>\u2022 Negative DAT</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 A positive DAT with anti-IgM specificity is a key laboratory finding in the diagnosis of CAS.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "fadf61ec",
      "audio": ""
    },
    {
      "text": "A 68-year-old man with a history of lymphoma presents with fatigue, jaundice, and splenomegaly. Peripheral blood smear shows spherocytes. Which of the following is the MOST likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Cold agglutinin disease (CAD)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Paroxysmal cold hemoglobinuria (PCH)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Warm autoimmune hemolytic anemia (WAIHA)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Microangiopathic hemolytic anemia (MAHA)",
          "correct": false
        }
      ],
      "correct_answer": "C. Warm autoimmune hemolytic anemia (WAIHA)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Warm autoimmune hemolytic anemia (WAIHA)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Cold agglutinin disease (CAD): Primarily presents with acrocyanosis and anemia, and blood smear often reveals agglutination.</li><li>\u2022 Option A. Cold agglutinin disease (CAD):</li><li>\u2022 Option B. Paroxysmal cold hemoglobinuria (PCH): Paroxysmal cold hemoglobinuria (PCH) is rare and typically presents with biphasic hemolysis and hemoglobinuria after cold exposure.</li><li>\u2022 Option B. Paroxysmal cold hemoglobinuria (PCH):</li><li>\u2022 Option D. Microangiopathic hemolytic anemia (MAHA): Presents with schistocytes on peripheral smear and is associated with underlying conditions like thrombotic thrombocytopenic purpura (TTP) or hemolytic uremic syndrome (HUS).</li><li>\u2022 Option D. Microangiopathic hemolytic anemia (MAHA):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 WAIHA is the most common type of autoimmune hemolytic anemia and can be associated with underlying lymphoproliferative disorders like lymphoma</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "556a756e",
      "audio": ""
    },
    {
      "text": "A 35-year-old patient with sickle cell disease (SCD) and a history of frequent vaso-occlusive crises is being considered for treatment with crizanlizumab, a monoclonal antibody that targets P-selectin. What is the PRIMARY mechanism of action of crizanlizumab in preventing vaso-occlusive crises in SCD?",
      "options": [
        {
          "label": "A",
          "text": "Increasing fetal hemoglobin (HbF) levels",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreasing red blood cell sickling",
          "correct": false
        },
        {
          "label": "C",
          "text": "Inhibiting platelet aggregation",
          "correct": false
        },
        {
          "label": "D",
          "text": "Blocking adhesive interactions between sickle cells and endothelial cells",
          "correct": true
        }
      ],
      "correct_answer": "D. Blocking adhesive interactions between sickle cells and endothelial cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Blocking adhesive interactions between sickle cells and endothelial cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increasing fetal hemoglobin (HbF) levels: Hydroxyurea, not crizanlizumab, is the primary medication used to increase HbF levels in sickle cell disease.</li><li>\u2022 Option A. Increasing fetal hemoglobin (HbF) levels:</li><li>\u2022 Option B. Decreasing red blood cell sickling: While reducing adhesion can indirectly help prevent sickling, crizanlizumab's primary mechanism is not directly targeting the sickling process itself.</li><li>\u2022 Option B. Decreasing red blood cell sickling:</li><li>\u2022 Option C. Inhibiting platelet aggregation: While platelets play a role in vaso-occlusion, crizanlizumab's primary target is P-selectin on endothelial cells, not platelets.</li><li>\u2022 Option C. Inhibiting platelet aggregation:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 P-selectin blockade is a novel therapeutic approach in SCD that targets the adhesive interactions involved in vaso-occlusion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "0994f1ce",
      "audio": ""
    },
    {
      "text": "An 11-year-old boy is brought to the physician by his mother because of worsening fatigue. His mother reports that he seems to have trouble keeping up with his older brothers when playing outside. Physical examination shows conjunctival pallor. A hemoglobin electrophoresis is performed. This patient's results are shown in comparison to those of a patient with known sickle cell anemia and a child with normal hemoglobin. Based on this electrophoresis, which of the following types of hemoglobin are dominant in this patient's blood?",
      "options": [
        {
          "label": "A",
          "text": "HbC only",
          "correct": false
        },
        {
          "label": "B",
          "text": "HbA and HbC",
          "correct": false
        },
        {
          "label": "C",
          "text": "HbA and HbS",
          "correct": false
        },
        {
          "label": "D",
          "text": "HbS and HbC",
          "correct": true
        }
      ],
      "correct_answer": "D. HbS and HbC",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/07/31/whatsapp-image-2024-07-31-at-50300-pm.jpeg"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) HbS and HbC</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. HbC only: Individuals homozygous for HbC have hemoglobin C disease, which typically manifests with mild anemia. The electrophoresis pattern of a patient with HbC disease would show a single thicker band that migrates even less than HbS.</li><li>\u2022 Option A. HbC only:</li><li>\u2022 Option B. HbA and HbC: Individuals with the hemoglobin C trait would have both HbA and HbC in their blood. Hemoglobin electrophoresis of this patient shows HbC but not HbA. Moreover, hemoglobin C trait is usually an asymptomatic carrier state, unlike this patient with fatigue.</li><li>\u2022 Option B. HbA and HbC:</li><li>\u2022 Option C. HbA and HbS: Individuals heterozygous for the sickle cell trait would have both HbA and HbS in their blood. Hemoglobin electrophoresis of this patient shows HbS but not HbA. Moreover, individuals heterozygous for the sickle cell trait are usually asymptomatic, unlike this patient with fatigue.</li><li>\u2022 Option C. HbA and HbS:</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "530c8818",
      "audio": ""
    },
    {
      "text": "A 28-year-old African American woman presents with mild anemia and complains of intermittent abdominal pain. On peripheral blood smear, target cells and rhomboid crystals are noted within red blood cells. Given the likely diagnosis, Which of the following amino acid changes is responsible for this condition?",
      "options": [
        {
          "label": "A",
          "text": "Glutamic acid to lysine",
          "correct": true
        },
        {
          "label": "B",
          "text": "Valine to glutamic acid",
          "correct": false
        },
        {
          "label": "C",
          "text": "Lysine to glutamic acid",
          "correct": false
        },
        {
          "label": "D",
          "text": "Glutamic acid to valine",
          "correct": false
        }
      ],
      "correct_answer": "A. Glutamic acid to lysine",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Glutamic acid to lysine</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Valine to glutamic acid: This substitution is the characteristic change for sickle cell anemia (HbS).</li><li>\u2022 Option B. Valine to glutamic acid:</li><li>\u2022 Option C. Lysine to glutamic acid: Swapping these two positively charged amino acids would likely have a minimal effect on hemoglobin function.</li><li>\u2022 Option C. Lysine to glutamic acid:</li><li>\u2022 Option D. Glutamic acid to valine: This substitution is also seen in HbS and leads to the polymerization of red blood cells.</li><li>\u2022 Option D. Glutamic acid to valine:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 HbC disease is a milder form of hemoglobinopathy compared to sickle cell disease, but it is important to distinguish it based on the specific amino acid substitution.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "e786964f",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman with G6PD deficiency presents with jaundice and fatigue. Her laboratory results show hemoglobin of 8 g/dL and elevated indirect bilirubin. Which of the following medications would be MOST likely to trigger this hemolytic episode?",
      "options": [
        {
          "label": "A",
          "text": "Acetaminophen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Penicillin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Ciprofloxacin",
          "correct": false
        },
        {
          "label": "D",
          "text": "Nitrofurantoin",
          "correct": true
        }
      ],
      "correct_answer": "D. Nitrofurantoin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Nitrofurantoin</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Acetaminophen : Acetaminophen is not a common trigger of G6PD deficiency-related hemolysis.</li><li>\u2022 Option A.</li><li>\u2022 Acetaminophen</li><li>\u2022 Option B. Penicillin : Penicillin is generally safe in G6PD deficiency.</li><li>\u2022 Option B.</li><li>\u2022 Penicillin</li><li>\u2022 Option C. Ciprofloxacin : Ciprofloxacin is not a common trigger of G6PD deficiency-related hemolysis.</li><li>\u2022 Option C.</li><li>\u2022 Ciprofloxacin</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 It is crucial to avoid medications that can trigger hemolysis in patients with G6PD deficiency.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dfe11c2f",
      "audio": ""
    },
    {
      "text": "A 15-year-old girl with hereditary spherocytosis presents with right upper quadrant pain. Ultrasound reveals gallstones. Which of the following is the most likely mechanism of gallstone formation in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Increased cholesterol secretion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreased bile acid synthesis",
          "correct": false
        },
        {
          "label": "C",
          "text": "Increased pigment excretion",
          "correct": true
        },
        {
          "label": "D",
          "text": "Decreased gallbladder motility",
          "correct": false
        }
      ],
      "correct_answer": "C. Increased pigment excretion",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Increased pigment excretion</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increased cholesterol secretion: While cholesterol is a major component of gallstones, increased secretion is not the primary culprit in HS.</li><li>\u2022 Option A. Increased cholesterol secretion:</li><li>\u2022 Option B. Decreased bile acid synthesis: Decreased bile acid synthesis can promote cholesterol gallstones, but it is not a major factor in pigment gallstone formation seen in HS.</li><li>\u2022 Option B. Decreased bile acid synthesis:</li><li>\u2022 Option D. Decreased gallbladder motility: Decreased gallbladder motility can contribute to gallstone formation, but it is not the most specific or common finding in HS.</li><li>\u2022 Option D. Decreased gallbladder motility:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Gallstones are a common complication of hereditary spherocytosis due to increased pigment excretion.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "04366519",
      "audio": ""
    },
    {
      "text": "A 40-year-old man presents with fatigue, abdominal pain, and dark urine, especially in the morning. Laboratory tests reveal hemoglobinuria and decreased levels of CD55 and CD59 on red blood cells. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Autoimmune hemolytic anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Glucose-6-phosphate dehydrogenase (G6PD) deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Paroxysmal nocturnal hemoglobinuria (PNH)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Sickle cell disease",
          "correct": false
        }
      ],
      "correct_answer": "C. Paroxysmal nocturnal hemoglobinuria (PNH)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Paroxysmal nocturnal hemoglobinuria (PNH)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Autoimmune hemolytic anemia: While it can present with anemia and hemolysis, it typically does not cause hemoglobinuria or have decreased CD55/CD59 levels.</li><li>\u2022 Option A. Autoimmune hemolytic anemia:</li><li>\u2022 Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: This usually presents with episodic hemolysis triggered by oxidative stress, not specifically at night.</li><li>\u2022 Option B. Glucose-6-phosphate dehydrogenase (G6PD) deficiency:</li><li>\u2022 Option D. Sickle cell disease: This is a genetic hemoglobinopathy with distinct clinical and laboratory findings.</li><li>\u2022 Option D. Sickle cell disease:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 PNH is a rare acquired hemolytic anemia characterized by intravascular hemolysis, often more pronounced at night, and decreased CD55 and CD59 levels on blood cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b88a03ef",
      "audio": ""
    },
    {
      "text": "Which of the following is the first-line treatment for paroxysmal nocturnal hemoglobinuria (PNH)?",
      "options": [
        {
          "label": "A",
          "text": "Prednisone",
          "correct": false
        },
        {
          "label": "B",
          "text": "Ravulizumab",
          "correct": true
        },
        {
          "label": "C",
          "text": "Rituximab",
          "correct": false
        },
        {
          "label": "D",
          "text": "Cyclosporine",
          "correct": false
        }
      ],
      "correct_answer": "B. Ravulizumab",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Ravulizumab</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Prednisone: While corticosteroids like prednisone may be used in some cases of autoimmune hemolytic anemia, they are not the first-line treatment for PNH. They are less effective than eculizumab or ravulizumab at controlling hemolysis and thrombosis.</li><li>\u2022 Option A. Prednisone:</li><li>\u2022 Option C. Rituximab: Rituximab is a monoclonal antibody that targets B cells. While it can be used in some autoimmune disorders, it is not indicated for PNH.</li><li>\u2022 Option C. Rituximab:</li><li>\u2022 Option D. Cyclosporine: Cyclosporine is an immunosuppressant used in various conditions, including organ transplantation and some autoimmune disorders. It has no direct effect on the complement system, which is the primary driver of PNH, and thus is not used in its treatment.</li><li>\u2022 Option D. Cyclosporine:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Eculizumab and ravulizumab have revolutionized the treatment of PNH by significantly reducing hemolysis, thrombosis risk, and improving quality of life.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "72e07db8",
      "audio": ""
    },
    {
      "text": "Flow cytometry in a patient with suspected aplastic anemia is most likely to reveal:",
      "options": [
        {
          "label": "A",
          "text": "Increased CD34+ cells",
          "correct": false
        },
        {
          "label": "B",
          "text": "Decreased or absent CD34+ cells",
          "correct": true
        },
        {
          "label": "C",
          "text": "Increased blasts",
          "correct": false
        },
        {
          "label": "D",
          "text": "Monoclonal B-cell population",
          "correct": false
        }
      ],
      "correct_answer": "B. Decreased or absent CD34+ cells",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Decreased or absent CD34+ cells</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Increased CD34+ cells: This would be seen in conditions with increased hematopoietic activity, such as recovery from chemotherapy or certain leukemias. It's not expected in aplastic anemia where the bone marrow is failing.</li><li>\u2022 Option A. Increased CD34+ cells:</li><li>\u2022 Option C. Increased blasts: Increased blasts (immature blood cells) would suggest acute leukemia or myelodysplastic syndrome (MDS), not aplastic anemia.</li><li>\u2022 Option C. Increased blasts:</li><li>\u2022 Option D. Monoclonal B-cell population: This finding would be more indicative of a lymphoproliferative disorder, such as chronic lymphocytic leukemia (CLL) or lymphoma, rather than aplastic anemia.</li><li>\u2022 Option D. Monoclonal B-cell population:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Flow cytometry can help confirm the diagnosis of aplastic anemia by demonstrating a lack of CD34+ cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "57cf5375",
      "audio": ""
    },
    {
      "text": "A 65-year-old vegan presents with fatigue, pallor, and numbness and tingling in their hands and feet. Which of the following laboratory findings would be MOST consistent with the suspected diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Microcytic anemia and normal methylmalonic acid (MMA) level",
          "correct": false
        },
        {
          "label": "B",
          "text": "Macrocytic anemia and elevated MMA level",
          "correct": true
        },
        {
          "label": "C",
          "text": "Macrocytic anemia and normal MMA level",
          "correct": false
        },
        {
          "label": "D",
          "text": "Normocytic anemia and elevated homocysteine level",
          "correct": false
        }
      ],
      "correct_answer": "B. Macrocytic anemia and elevated MMA level",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Macrocytic anemia and elevated MMA level</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Microcytic anemia and normal methylmalonic acid (MMA) level: Microcytic anemia is associated with iron deficiency, not B12 deficiency.</li><li>\u2022 Option A. Microcytic anemia and normal methylmalonic acid (MMA) level:</li><li>\u2022 Option C. Macrocytic anemia and normal MMA level: While macrocytic anemia is consistent with B12 deficiency, normal MMA levels would not be expected.</li><li>\u2022 Option C. Macrocytic anemia and normal MMA level:</li><li>\u2022 Option D. Normocytic anemia and elevated homocysteine level: Normocytic anemia is not typical of B12 deficiency, and while homocysteine can be elevated in both B12 and folate deficiencies, it's not specific for B12.</li><li>\u2022 Option D. Normocytic anemia and elevated homocysteine level:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Vitamin B12 deficiency should be suspected in vegans presenting with neurological symptoms and macrocytic anemia. Elevated MMA levels are a specific marker for B12 deficiency.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "703d3190",
      "audio": ""
    },
    {
      "text": "Which of the following medications is MOST likely to interfere with folate metabolism and potentially lead to folate deficiency?",
      "options": [
        {
          "label": "A",
          "text": "Aspirin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Metformin",
          "correct": false
        },
        {
          "label": "C",
          "text": "Methotrexate",
          "correct": true
        },
        {
          "label": "D",
          "text": "Atorvastatin",
          "correct": false
        }
      ],
      "correct_answer": "C. Methotrexate",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Methotrexate</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Aspirin: While aspirin can cause some minor interference with folate absorption at very high doses, it's not a major contributor to folate deficiency at typical doses.</li><li>\u2022 Option A. Aspirin:</li><li>\u2022 Option B. Metformin: Metformin primarily affects glucose metabolism and doesn't have a direct impact on folate metabolism. However, long-term metformin use has been associated with mild decreases in vitamin B12 levels, which can sometimes be confused with folate deficiency.</li><li>\u2022 Option B. Metformin:</li><li>\u2022 Option D. Atorvastatin: Atorvastatin is a cholesterol-lowering medication (statin) and does not interfere with folate metabolism.</li><li>\u2022 Option D. Atorvastatin:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 While all medications should be reviewed when a patient presents with folate deficiency, methotrexate stands out as the most likely culprit due to its direct inhibitory effect on dihydrofolate reductase, a key enzyme in folate metabolism.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b51e77e",
      "audio": ""
    },
    {
      "text": "Which of the following genetic modifications on chromosome 9 leads to the formation of the B antigen?",
      "options": [
        {
          "label": "A",
          "text": "Addition of N-acetylgalactosamine (GalNAc) to the H antigen",
          "correct": false
        },
        {
          "label": "B",
          "text": "Addition of galactose (Gal) to the H antigen",
          "correct": true
        },
        {
          "label": "C",
          "text": "Removal of fucose from the H antigen",
          "correct": false
        },
        {
          "label": "D",
          "text": "Absence of both GalNAc and Gal on the H antigen",
          "correct": false
        }
      ],
      "correct_answer": "B. Addition of galactose (Gal) to the H antigen",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Addition of galactose (Gal) to the H antigen</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Addition of N-acetylgalactosamine (GalNAc) to the H antigen: This modification results in the formation of the A antigen.</li><li>\u2022 Option A. Addition of N-acetylgalactosamine (GalNAc) to the H antigen:</li><li>\u2022 Option C. Removal of fucose from the H antigen: While removal of fucose is a step in the formation of both A and B antigens, it's not the final step for the B antigen.</li><li>\u2022 Option C. Removal of fucose from the H antigen:</li><li>\u2022 Option D. Absence of both GalNAc and Gal on the H antigen: This results in the O blood group, where neither A nor B antigens are present.</li><li>\u2022 Option D. Absence of both GalNAc and Gal on the H antigen:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The A and B antigens are formed by modifications of the H antigen.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "3a78bcb7",
      "audio": ""
    },
    {
      "text": "A patient experiences a delayed hemolytic transfusion reaction (DHTR) 5 days after a blood transfusion. Which of the following blood group systems is most likely responsible?",
      "options": [
        {
          "label": "A",
          "text": "Kell",
          "correct": false
        },
        {
          "label": "B",
          "text": "Kidd",
          "correct": true
        },
        {
          "label": "C",
          "text": "MNS",
          "correct": false
        },
        {
          "label": "D",
          "text": "Lewis",
          "correct": false
        }
      ],
      "correct_answer": "B. Kidd",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Kidd</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Kell: While Kell antibodies can cause severe hemolytic reactions, these are typically acute rather than delayed.</li><li>\u2022 Option A. Kell:</li><li>\u2022 Option C. MNS: MNS antibodies can cause delayed hemolytic transfusion reactions, but they are relatively rare compared to Kidd antibodies.</li><li>\u2022 Option C. MNS:</li><li>\u2022 Option D. Lewis: Lewis antibodies are naturally occurring and typically of the IgM isotype, which are generally not considered clinically significant in transfusions.</li><li>\u2022 Option D. Lewis:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Kidd antibodies are typically IgG and can cause severe delayed reactions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "95e579c7",
      "audio": ""
    },
    {
      "text": "Which of the following antigen is resistant to P. vivax/knowlesi?",
      "options": [
        {
          "label": "A",
          "text": "K/k",
          "correct": false
        },
        {
          "label": "B",
          "text": "DARC (Duffy Antigen Receptor for Chemokines)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Lewis Ag",
          "correct": false
        },
        {
          "label": "D",
          "text": "A antigen",
          "correct": false
        }
      ],
      "correct_answer": "B. DARC (Duffy Antigen Receptor for Chemokines)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) DARC (Duffy Antigen Receptor for Chemokines)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. K/k: Kell antigens are a group of antigens found on red blood cells. They are not involved in malaria resistance.</li><li>\u2022 Option A. K/k:</li><li>\u2022 Option C. Lewis Ag: Lewis antigens are present in body fluids and can be adsorbed onto red blood cells. They do not play a role in malaria resistance.</li><li>\u2022 Option C. Lewis Ag:</li><li>\u2022 Option D. A antigen: The A antigen is part of the ABO blood group system and determines blood type. It has no relationship to malaria susceptibility.</li><li>\u2022 Option D. A antigen:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The Duffy antigen receptor for chemokines (DARC) is essential for P. vivax and P. knowlesi malaria parasites to invade red blood cells. Individuals without this receptor are naturally resistant to these types of malaria.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "6d76ab14",
      "audio": ""
    },
    {
      "text": "A patient's blood sample is mixed with Anit-A/B/D and the findings are shown below. What is the patient's blood type?",
      "options": [
        {
          "label": "A",
          "text": "A+",
          "correct": false
        },
        {
          "label": "B",
          "text": "B+",
          "correct": true
        },
        {
          "label": "C",
          "text": "AB+",
          "correct": false
        },
        {
          "label": "D",
          "text": "O-",
          "correct": false
        }
      ],
      "correct_answer": "B. B+",
      "question_images": [
        "https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/01/screenshot-2024-08-01-103344.png"
      ],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) B+</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "c593a786",
      "audio": ""
    },
    {
      "text": "A 30-year-old woman presents to the clinic with a two-week history of easy bruising and pinprick red spots on her lower legs. She denies any recent injuries or medication use. On examination, she has multiple petechiae on her skin and mucous membranes. Blood investigations except low platelet count, imagings turned out to be normal. What's the likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Aplastic anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Immune thrombocytopenia (ITP)",
          "correct": true
        },
        {
          "label": "C",
          "text": "Myelodysplastic syndrome (MDS)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Thrombotic microangiopathy (TMA)",
          "correct": false
        }
      ],
      "correct_answer": "B. Immune thrombocytopenia (ITP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Immune thrombocytopenia (ITP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Aplastic anemia : While it can cause thrombocytopenia, it also affects other cell lines (red blood cells and white blood cells).</li><li>\u2022 Option A. Aplastic anemia</li><li>\u2022 Option C. Myelodysplastic syndrome (MDS) : MDS can cause thrombocytopenia, but it is more common in older adults and often presents with other cytopenias.</li><li>\u2022 Option C. Myelodysplastic syndrome (MDS)</li><li>\u2022 Option D. Thrombotic microangiopathy (TMA) : TMA causes thrombocytopenia through a different mechanism (platelet consumption in microvascular thrombi).</li><li>\u2022 Option D. Thrombotic microangiopathy (TMA)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 ITP is a diagnosis of exclusion, meaning other causes of thrombocytopenia need to be ruled out.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "40e992c2",
      "audio": ""
    },
    {
      "text": "A 45-year-old asymptomatic woman has a routine complete blood count (CBC) which shows a platelet count of 80,000/\u00b5L. Peripheral blood smear shows large platelet clumps. Given the likely diagnosis, Which of the following is the most appropriate next step in the management of this patient?",
      "options": [
        {
          "label": "A",
          "text": "Repeat the CBC in a sodium citrate tube",
          "correct": true
        },
        {
          "label": "B",
          "text": "Start corticosteroids for ITP",
          "correct": false
        },
        {
          "label": "C",
          "text": "Order a bone marrow biopsy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Begin heparin therapy for HIT",
          "correct": false
        }
      ],
      "correct_answer": "A. Repeat the CBC in a sodium citrate tube",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Repeat the CBC in a sodium citrate tube</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Start corticosteroids for ITP : Corticosteroids are used to treat ITP, but this is not appropriate until pseudothrombocytopenia is ruled out.</li><li>\u2022 Option B. Start corticosteroids for ITP</li><li>\u2022 Option C. Order a bone marrow biopsy : A bone marrow biopsy is not necessary for the diagnosis of pseudothrombocytopenia.</li><li>\u2022 Option C. Order a bone marrow biopsy</li><li>\u2022 Option D. Begin heparin therapy for HIT : Heparin therapy is contraindicated in HIT and should not be started until this diagnosis is ruled out.</li><li>\u2022 Option D. Begin heparin therapy for HIT</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective :</li><li>\u2022 Repeating the CBC in a citrate tube is a simple and effective way to confirm pseudothrombocytopenia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "60fcaaff",
      "audio": ""
    },
    {
      "text": "A 55-year-old male with a recent diagnosis of chronic lymphocytic leukemia (CLL) presents with fatigue, easy bruising, and petechiae. His platelet count is 20,000/\u00b5L. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Primary immune thrombocytopenia (ITP)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Drug-induced thrombocytopenia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Heparin-induced thrombocytopenia (HIT)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Secondary ITP associated with CLL",
          "correct": true
        }
      ],
      "correct_answer": "D. Secondary ITP associated with CLL",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Secondary ITP associated with CLL</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Primary immune thrombocytopenia (ITP): While ITP presents with isolated thrombocytopenia, the presence of CLL suggests a secondary cause in this case.</li><li>\u2022 Option</li><li>\u2022 A. Primary immune thrombocytopenia (ITP):</li><li>\u2022 Option B. Drug-induced thrombocytopenia: There is no mention of recent medication use to suggest this diagnosis.</li><li>\u2022 Option</li><li>\u2022 B. Drug-induced thrombocytopenia:</li><li>\u2022 Option C. Heparin-induced thrombocytopenia (HIT): HIT is an immune-mediated reaction to heparin, which is not mentioned in the patient's history.</li><li>\u2022 Option C.</li><li>\u2022 Heparin-induced thrombocytopenia (HIT):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Secondary ITP can be caused by various underlying conditions, including lymphoproliferative disorders like CLL.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "11c527ba",
      "audio": ""
    },
    {
      "text": "A 42-year-old woman with a 5-year history of chronic ITP has persistent thrombocytopenia (25,000/\u00b5L) despite prior treatments with corticosteroids, IVIg, and TPO-RAs. She experiences frequent bleeding and seeks further management options. Which of the following is the next step in her management?",
      "options": [
        {
          "label": "A",
          "text": "Rituximab infusion",
          "correct": false
        },
        {
          "label": "B",
          "text": "Splenectomy",
          "correct": true
        },
        {
          "label": "C",
          "text": "Danazol therapy",
          "correct": false
        },
        {
          "label": "D",
          "text": "Fostamatinib therapy",
          "correct": false
        }
      ],
      "correct_answer": "B. Splenectomy",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Splenectomy</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Rituximab infusion: While rituximab can be effective in some patients, its response rate is lower than splenectomy and the onset of action is delayed. It also carries potential for serious side effects like infections and infusion reactions.</li><li>\u2022 Option</li><li>\u2022 A. Rituximab infusion:</li><li>\u2022 Option C. Danazol therapy: Danazol is an older medication with limited evidence of efficacy in ITP and potential for masculinizing side effects in women, making it a less preferred option.</li><li>\u2022 Option</li><li>\u2022 C. Danazol therapy:</li><li>\u2022 Option D. Fostamatinib therapy: This is a newer option with promising results, but it has less long-term data than splenectomy and may have adverse effects like hypertension, diarrhea, and hepatotoxicity.</li><li>\u2022 Option</li><li>\u2022 D. Fostamatinib therapy:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 In patients with chronic ITP refractory to initial therapies, splenectomy offers the highest chance of long-term remission, but it should be considered after weighing the risks and benefits of surgery. Other options like rituximab and fostamatinib may be considered in select cases, while danazol is less commonly used due to its limited efficacy and side effect profile.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ed3ef11c",
      "audio": ""
    },
    {
      "text": "A 52-year-old woman develops new-onset thrombocytopenia and thrombosis 6 days after initiating unfractionated heparin (UFH) for DVT prophylaxis following knee replacement surgery. Her medical history is significant for hypertension and osteoarthritis. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Immune Thrombocytopenic Purpura (ITP)",
          "correct": false
        },
        {
          "label": "B",
          "text": "Type I Heparin-Induced Thrombocytopenia (HIT)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Type II Heparin-Induced Thrombocytopenia (HIT)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Thrombotic Thrombocytopenic Purpura (TTP)",
          "correct": false
        }
      ],
      "correct_answer": "C. Type II Heparin-Induced Thrombocytopenia (HIT)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Type II Heparin-Induced Thrombocytopenia (HIT)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Immune Thrombocytopenic Purpura (ITP) : ITP is an autoimmune disorder that can cause thrombocytopenia but is not typically associated with thrombosis.</li><li>\u2022 Option A. Immune Thrombocytopenic Purpura (ITP)</li><li>\u2022 Option B. Type I Heparin-Induced Thrombocytopenia (HIT): This is a non-immune mediated form of HIT that usually occurs within the first 2 days of heparin exposure and is not associated with thrombosis.</li><li>\u2022 Option B. Type I Heparin-Induced Thrombocytopenia (HIT):</li><li>\u2022 Option D. Thrombotic Thrombocytopenic Purpura (TTP): TTP is a rare disorder characterized by thrombocytopenia, microangiopathic hemolytic anemia, and neurologic symptoms. It is not typically associated with heparin use.</li><li>\u2022 Option D. Thrombotic Thrombocytopenic Purpura (TTP):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 New-onset thrombocytopenia and thrombosis in a patient recently started on heparin should raise suspicion for Type II HIT, which warrants immediate discontinuation of heparin and initiation of alternative anticoagulation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9608ddbc",
      "audio": ""
    },
    {
      "text": "Which of the following is NOT a typical clinical feature of Thrombotic Microangiopathy (TMA)?",
      "options": [
        {
          "label": "A",
          "text": "Thrombocytopenia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Microangiopathic hemolytic anemia (MAHA)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Prolonged PT and PTT",
          "correct": true
        },
        {
          "label": "D",
          "text": "Renal dysfunction",
          "correct": false
        }
      ],
      "correct_answer": "C. Prolonged PT and PTT",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Prolonged PT and PTT</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Thrombocytopenia : A key feature of TMA due to platelet consumption in microthrombi.</li><li>\u2022 Option A.</li><li>\u2022 Thrombocytopenia</li><li>\u2022 Option B. Microangiopathic hemolytic anemia (MAHA) : Also a key feature of TMA due to mechanical damage to red blood cells.</li><li>\u2022 Option B. Microangiopathic hemolytic anemia (MAHA)</li><li>\u2022 Option D. Renal dysfunction : Can occur due to microthrombi formation in the kidneys.</li><li>\u2022 Option D. Renal</li><li>\u2022 dysfunction</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Normal PT and PTT help differentiate TMA from other conditions like DIC, which typically present with abnormal coagulation tests.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "cd58e84e",
      "audio": ""
    },
    {
      "text": "A patient with a history of malignant hypertension presents with MAHA, thrombocytopenia, and acute kidney injury. What is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "TTP",
          "correct": false
        },
        {
          "label": "B",
          "text": "HUS",
          "correct": false
        },
        {
          "label": "C",
          "text": "DIC",
          "correct": false
        },
        {
          "label": "D",
          "text": "TMA",
          "correct": true
        }
      ],
      "correct_answer": "D. TMA",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) TMA</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. TTP (Thrombotic Thrombocytopenic Purpura): While TTP can present with MAHA, thrombocytopenia, and acute kidney injury, it is typically associated with a deficiency of the ADAMTS13 enzyme. This patient's history of malignant hypertension makes TMA a more likely diagnosis.</li><li>\u2022 Option</li><li>\u2022 A. TTP (Thrombotic Thrombocytopenic Purpura):</li><li>\u2022 Option B. HUS (Hemolytic Uremic Syndrome): HUS is often associated with Shiga-toxin producing E. coli infection and commonly presents with bloody diarrhea. The patient's history does not suggest this.</li><li>\u2022 Option</li><li>\u2022 B. HUS (Hemolytic Uremic Syndrome):</li><li>\u2022 Option C. DIC (Disseminated Intravascular Coagulation): DIC is a consumptive coagulopathy triggered by a systemic illness (e.g., sepsis, malignancy). While it can cause MAHA and thrombocytopenia, it would typically present with abnormal coagulation parameters (prolonged PT/PTT, low fibrinogen) which are not mentioned in this scenario.</li><li>\u2022 Option</li><li>\u2022 C. DIC (Disseminated Intravascular Coagulation):</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 It's important to consider secondary causes of TMA, such as malignant hypertension, in patients with relevant risk factors.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "04575a9a",
      "audio": ""
    },
    {
      "text": "Which of the following genetic mutations is NOT typically associated with familial atypical HUS?",
      "options": [
        {
          "label": "A",
          "text": "CFH",
          "correct": false
        },
        {
          "label": "B",
          "text": "CFI",
          "correct": false
        },
        {
          "label": "C",
          "text": "CD46",
          "correct": false
        },
        {
          "label": "D",
          "text": "STXBP5",
          "correct": true
        }
      ],
      "correct_answer": "D. STXBP5",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) STXBP5</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. CFH, Option B. CFI and Option C. CD46: These genes all encode complement regulatory proteins, and mutations in them can lead to familial aHUS.</li><li>\u2022 Option</li><li>\u2022 A. CFH, Option</li><li>\u2022 B. CFI</li><li>\u2022 Option</li><li>\u2022 C. CD46:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Familial atypical HUS is a genetically heterogeneous disorder with mutations in several complement regulatory genes. Recognizing the role of these genes is essential for accurate diagnosis, genetic counseling, and potential targeted therapies. While STXBP5 mutations are more commonly associated with a neurological disorder and are not typically seen in familial cases.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "07d812ed",
      "audio": ""
    },
    {
      "text": "A 4-month-old infant presents with lethargy, hypotonia, and developmental delay. Laboratory investigations reveal megaloblastic anemia, elevated homocysteine and methylmalonic acid (MMA) levels. Which of the following conditions is MOST LIKELY to predispose this infant to thrombotic microangiopathy (TMA)?",
      "options": [
        {
          "label": "A",
          "text": "Methylmalonic acidemia due to MMACHC mutation",
          "correct": true
        },
        {
          "label": "B",
          "text": "Dihydrofolate reductase (DHFR) deficiency",
          "correct": false
        },
        {
          "label": "C",
          "text": "Maple syrup urine disease (MSUD)",
          "correct": false
        },
        {
          "label": "D",
          "text": "Tyrosinemia type I",
          "correct": false
        }
      ],
      "correct_answer": "A. Methylmalonic acidemia due to MMACHC mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Methylmalonic acidemia due to MMACHC mutation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Dihydrofolate reductase (DHFR) deficiency : DHFR deficiency primarily affects folate metabolism and does not directly predispose to TMA.</li><li>\u2022 Option B. Dihydrofolate reductase (DHFR) deficiency</li><li>\u2022 Option C. Maple syrup urine disease (MSUD) : MSUD is an amino acid disorder and is not associated with increased risk of TMA.</li><li>\u2022 Option C. Maple syrup urine disease (MSUD)</li><li>\u2022 Option D. Tyrosinemia type I : Tyrosinemia type I is a metabolic disorder affecting tyrosine metabolism and does not typically predispose to TMA.</li><li>\u2022 Option D. Tyrosinemia type I</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 MMACHC mutations can lead to elevated homocysteine levels, which increases the risk of developing thrombotic microangiopathy (TMA) in affected individuals.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9d9b5342",
      "audio": ""
    },
    {
      "text": "A 30-year-old female presents with a history of heavy menstrual bleeding since menarche. She also reports easy bruising and prolonged bleeding after minor cuts. Physical examination reveals scattered petechiae. Which of the following tests is most likely to be diagnostic?",
      "options": [
        {
          "label": "A",
          "text": "Ristocetin cofactor activity",
          "correct": false
        },
        {
          "label": "B",
          "text": "Platelet aggregation studies",
          "correct": true
        },
        {
          "label": "C",
          "text": "Factor VIII assay",
          "correct": false
        },
        {
          "label": "D",
          "text": "Bone marrow biopsy",
          "correct": false
        }
      ],
      "correct_answer": "B. Platelet aggregation studies",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Platelet aggregation studies</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Ristocetin cofactor activity : This test measures the function of von Willebrand factor (vWF) and is used in the diagnosis of von Willebrand disease.</li><li>\u2022 Option A. Ristocetin cofactor activity</li><li>\u2022 Option C. Factor VIII assay : This test is used to diagnose hemophilia A.</li><li>\u2022 Option C. Factor VIII assay</li><li>\u2022 Option D. Bone marrow biopsy : This test is not indicated in the initial workup of suspected Glanzmann thrombasthenia.</li><li>\u2022 Option D. Bone marrow biopsy</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Platelet aggregation studies are the definitive test for diagnosing Glanzmann thrombasthenia.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "658cb1fd",
      "audio": ""
    },
    {
      "text": "A 4-year-old child presents with recurrent pyogenic skin and respiratory infections, silver-grey hair, and nystagmus. Peripheral blood smear reveals giant granules in neutrophils. Given the likely diagnosis, Which of the following infections is MOST frequently associated with this condition?",
      "options": [
        {
          "label": "A",
          "text": "Staphylococcus aureus",
          "correct": true
        },
        {
          "label": "B",
          "text": "Streptococcus pneumoniae",
          "correct": false
        },
        {
          "label": "C",
          "text": "Pseudomonas aeruginosa",
          "correct": false
        },
        {
          "label": "D",
          "text": "Candida albicans",
          "correct": false
        }
      ],
      "correct_answer": "A. Staphylococcus aureus",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Staphylococcus aureus</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Streptococcus pneumoniae: While patients with Chediak-Higashi syndrome may be more susceptible to infections in general, there isn't a specific predisposition towards Streptococcus pneumoniae compared to Staphylococcus aureus.</li><li>\u2022 Option B. Streptococcus pneumoniae:</li><li>\u2022 Option C. Pseudomonas aeruginosa: Pseudomonas is more commonly associated with patients with cystic fibrosis or other immunocompromised states. It's not a hallmark infection for Chediak-Higashi.</li><li>\u2022 Option C. Pseudomonas aeruginosa:</li><li>\u2022 Option D. Candida albicans: This is a fungal infection, and while Chediak-Higashi syndrome patients may be more susceptible to infections overall, bacterial infections (especially those caused by Staphylococcus aureus) are of greater concern.</li><li>\u2022 Option D. Candida albicans:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Recurrent Staphylococcus aureus infections are a hallmark of Chediak-Higashi syndrome.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ae1af64d",
      "audio": ""
    },
    {
      "text": "A 35-year-old man with a history of easy bruising and prolonged bleeding after minor procedures undergoes laboratory testing. The results reveal a normal von Willebrand factor (vWF) antigen level, but a decreased vWF ristocetin cofactor activity (RCoF). Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Von Willebrand disease (VWD) type 1",
          "correct": false
        },
        {
          "label": "B",
          "text": "Von Willebrand disease (VWD) type 2",
          "correct": true
        },
        {
          "label": "C",
          "text": "Von Willebrand disease (VWD) type 3",
          "correct": false
        },
        {
          "label": "D",
          "text": "Acquired von Willebrand syndrome",
          "correct": false
        }
      ],
      "correct_answer": "B. Von Willebrand disease (VWD) type 2",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Von Willebrand disease (VWD) type 2</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Von Willebrand disease (VWD) type 1: In VWD type 1, both vWF antigen and RCoF levels are decreased proportionally, not just the RCoF.</li><li>\u2022 Option A. Von Willebrand disease (VWD) type 1:</li><li>\u2022 Option C. Von Willebrand disease (VWD) type 3: This is the most severe form of VWD with a near-complete absence of vWF, so both antigen and RCoF would be very low.</li><li>\u2022 Option C. Von Willebrand disease (VWD) type 3:</li><li>\u2022 Option D. Acquired von Willebrand syndrome: While this can mimic VWD, it is usually associated with underlying conditions like lymphoproliferative disorders, autoimmune diseases, or certain medications.</li><li>\u2022 Option D. Acquired von Willebrand syndrome:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 A normal vWF antigen level with a decreased RCoF strongly suggests a qualitative defect in vWF, which is characteristic of VWD type 2. Further testing can determine the specific subtype (2A, 2B, 2M, or 2N).</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bf1aedbf",
      "audio": ""
    },
    {
      "text": "Which of the following coagulation factors are increased by the administration of DDAVP?",
      "options": [
        {
          "label": "A",
          "text": "Factor VIII only",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor IX only",
          "correct": false
        },
        {
          "label": "C",
          "text": "Both Factor VIII and von Willebrand Factor (vWF)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Factor VIII, vWF, and Factor IX",
          "correct": false
        }
      ],
      "correct_answer": "C. Both Factor VIII and von Willebrand Factor (vWF)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Both Factor VIII and von Willebrand Factor (vWF)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Factor VIII only : While DDAVP does increase Factor VIII, it also increases vWF.</li><li>\u2022 Option A. Factor VIII only</li><li>\u2022 Option B. Factor IX only : DDAVP does not affect Factor IX levels.</li><li>\u2022 Option B. Factor IX only</li><li>\u2022 Option D. Factor VIII, vWF, and Factor IX : This is incorrect because, as mentioned above, DDAVP does not affect Factor IX levels.</li><li>\u2022 Option D. Factor VIII, vWF, and Factor IX</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective :</li><li>\u2022 DDAVP is a useful therapeutic agent in certain bleeding disorders, particularly mild hemophilia A and some types of von Willebrand disease (VWD), due to its ability to increase the levels of both Factor VIII and vWF. Understanding its mechanism of action is crucial for selecting appropriate patients for treatment and anticipating its effects.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b43f29df",
      "audio": ""
    },
    {
      "text": "A 22-year-old man with a history of frequent nosebleeds and prolonged bleeding after a tooth extraction presents with recurrent, painless bloody urine. Examination reveals multiple hematomas and decreased range of motion with crepitus in both ankles. Laboratory studies show a normal platelet count, prolonged partial thromboplastin time (PTT), and hematuria without RBC casts. An x-ray of the pelvis shows no abnormalities. Further evaluation of this patient is most likely to show which of the following findings?",
      "options": [
        {
          "label": "A",
          "text": "Evasive behavior when asked about the hematomas",
          "correct": false
        },
        {
          "label": "B",
          "text": "History of spontaneous hematomas in paternal grandmother",
          "correct": false
        },
        {
          "label": "C",
          "text": "Petechiae in the oropharynx",
          "correct": false
        },
        {
          "label": "D",
          "text": "Intraarticular iron deposition",
          "correct": true
        }
      ],
      "correct_answer": "D. Intraarticular iron deposition",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Intraarticular iron deposition</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Evasive behavior when asked about the hematomas: While this might be present in some cases, it's not specific to hemophilia and doesn't help confirm the diagnosis.</li><li>\u2022 Option A. Evasive behavior when asked about the hematomas:</li><li>\u2022 Option B. History of spontaneous hematomas in paternal grandmother: While hemophilia is often inherited, a family history alone is not enough to diagnose the condition. Direct testing for factor deficiencies is needed.</li><li>\u2022 Option B. History of spontaneous hematomas in paternal grandmother:</li><li>\u2022 Option C. Petechiae in the oropharynx: Petechiae are typically associated with thrombocytopenia (low platelet count), not hemophilia. This patient's platelet count is normal.</li><li>\u2022 Option C. Petechiae in the oropharynx:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 In a patient with suspected hemophilia, further evaluation with imaging studies like MRI or ultrasound is essential to assess joint damage and confirm the diagnosis of hemophilic arthropathy. A positive family history can raise suspicion, but definitive diagnosis requires factor assays.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "4b84f441",
      "audio": ""
    },
    {
      "text": "A 28-year-old male presents with a history of mild bleeding tendencies since childhood, primarily after trauma or surgery. He is found to have prolonged PT and aPTT, both of which correct with mixing studies. Which of the following genetic mutations is most likely associated with his condition?",
      "options": [
        {
          "label": "A",
          "text": "Factor VIII gene mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "Factor V gene mutation",
          "correct": false
        },
        {
          "label": "C",
          "text": "LMAN1 gene mutation",
          "correct": true
        },
        {
          "label": "D",
          "text": "Prothrombin gene mutation",
          "correct": false
        }
      ],
      "correct_answer": "C. LMAN1 gene mutation",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) LMAN1 gene mutation</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Factor VIII gene mutation : Causes hemophilia A, with isolated prolongation of aPTT.</li><li>\u2022 Option A. Factor VIII gene mutation</li><li>\u2022 Option B. Factor V gene mutation : Causes factor V deficiency, with isolated prolongation of PT.</li><li>\u2022 Option B. Factor V gene mutation</li><li>\u2022 Option D. Prothrombin gene mutation : Causes prothrombin deficiency, with isolated prolongation of PT.</li><li>\u2022 Option D. Prothrombin gene mutation</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Combined factor V and factor VIII deficiency is associated with mutations in the LMAN1 gene, leading to mild bleeding tendencies.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8ad0ae74",
      "audio": ""
    },
    {
      "text": "Which blood additive provides the longest shelf life for stored red blood cells?",
      "options": [
        {
          "label": "A",
          "text": "ACD (Acid citrate dextrose)",
          "correct": false
        },
        {
          "label": "B",
          "text": "CPD (Citrate phosphate dextrose)",
          "correct": false
        },
        {
          "label": "C",
          "text": "CP2D (Citrate phosphate double dextrose)",
          "correct": false
        },
        {
          "label": "D",
          "text": "SAGM (Saline adenine glucose mannitol)",
          "correct": true
        }
      ],
      "correct_answer": "D. SAGM (Saline adenine glucose mannitol)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) SAGM (Saline adenine glucose mannitol)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. ACD (Acid citrate dextrose): This was one of the earliest preservatives and has a relatively short shelf life (21 days). The citrate acts as an anticoagulant, while dextrose provides energy for the red blood cells.</li><li>\u2022 Option A. ACD (Acid citrate dextrose):</li><li>\u2022 Option B. CPD (Citrate phosphate dextrose): This is an improvement over ACD due to the addition of phosphate, which acts as a buffer to maintain pH. However, it still has a relatively short shelf life (21 days).</li><li>\u2022 Option B. CPD (Citrate phosphate dextrose):</li><li>\u2022 Option C. CP2D (Citrate phosphate double dextrose): This has double the amount of dextrose compared to CPD, providing more energy for the red blood cells and extending the shelf life slightly (28 days).</li><li>\u2022 Option C. CP2D (Citrate phosphate double dextrose):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 SAGM is the additive that provides the longest shelf life for stored red blood cells.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "023f9f0e",
      "audio": ""
    },
    {
      "text": "What is the main advantage of single-donor platelets (SDPs) over random-donor platelets (RDPs)?",
      "options": [
        {
          "label": "A",
          "text": "Lower cost",
          "correct": false
        },
        {
          "label": "B",
          "text": "Reduced risk of alloimmunization",
          "correct": true
        },
        {
          "label": "C",
          "text": "Higher platelet increment",
          "correct": false
        },
        {
          "label": "D",
          "text": "Longer shelf life",
          "correct": false
        }
      ],
      "correct_answer": "B. Reduced risk of alloimmunization",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Reduced risk of alloimmunization</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Lower cost: SDPs are typically more expensive to produce than RDPs because they require apheresis, a specialized blood collection procedure.</li><li>\u2022 Option A. Lower cost:</li><li>\u2022 Option C. Higher platelet increment: While some studies have shown slightly higher platelet increments with SDPs, the difference is not always clinically significant, and the overall efficacy in preventing bleeding is similar between SDPs and RDPs.</li><li>\u2022 Option C. Higher platelet increment:</li><li>\u2022 Option D. Longer shelf life: Both SDPs and RDPs have similar shelf lives, typically around 5 days when stored properly.</li><li>\u2022 Option D. Longer shelf life:</li><li>\u2022 Educational objective:</li><li>\u2022 Educational objective:</li><li>\u2022 SDPs are preferred to reduce the risk of alloimmunization in patients who may require multiple transfusions.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "8cca6c13",
      "audio": ""
    },
    {
      "text": "A patient with severe liver disease presents with a prolonged prothrombin time (PT) and is scheduled for an invasive procedure. Which of the following is the most appropriate blood product for correcting their coagulopathy?",
      "options": [
        {
          "label": "A",
          "text": "Cryoprecipitate",
          "correct": false
        },
        {
          "label": "B",
          "text": "Prothrombin complex concentrate (PCC)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Fresh frozen plasma (FFP)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Platelet concentrate",
          "correct": false
        }
      ],
      "correct_answer": "C. Fresh frozen plasma (FFP)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Fresh frozen plasma (FFP)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Cryoprecipitate: While cryoprecipitate is a source of fibrinogen and factor VIII, it would not address the multiple coagulation factor deficiencies commonly seen in liver disease.</li><li>\u2022 Option A. Cryoprecipitate:</li><li>\u2022 Option B. Prothrombin Complex Concentrate (PCC): PCC contains vitamin K-dependent clotting factors (II, VII, IX, and X), but patients with liver disease may also have deficiencies in other factors not included in PCC.</li><li>\u2022 Option B. Prothrombin Complex Concentrate (PCC):</li><li>\u2022 Option D. Platelet concentrate: Platelets are used to treat thrombocytopenia (low platelet count), not coagulation factor deficiencies. While liver disease can cause thrombocytopenia, it is not the primary concern in this scenario where the patient has a prolonged PT.</li><li>\u2022 Option D. Platelet concentrate:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 FFP is the preferred blood product for correcting coagulopathy in liver disease due to its comprehensive coagulation factor content.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "2d11d86b",
      "audio": ""
    },
    {
      "text": "A patient with a history of severe febrile non-hemolytic transfusion reactions (FNHTR) is scheduled for surgery and requires a red blood cell (RBC) transfusion. The blood bank is unable to provide leukoreduced RBCs due to limited supply. Which of the following alternative methods could be considered to potentially reduce the risk of FNHTR in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Irradiation of RBCs",
          "correct": false
        },
        {
          "label": "B",
          "text": "Washing of RBCs",
          "correct": false
        },
        {
          "label": "C",
          "text": "UVB-treated RBCs",
          "correct": true
        },
        {
          "label": "D",
          "text": "Plasmapheresis of RBCs",
          "correct": false
        }
      ],
      "correct_answer": "C. UVB-treated RBCs",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) UVB-treated RBCs</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Irradiation of RBCs: Irradiation is primarily used to prevent transfusion-associated graft-versus-host disease (TA-GVHD) in immunocompromised patients. It does not specifically address the risk of FNHTR.</li><li>\u2022 Option A. Irradiation of RBCs:</li><li>\u2022 Option B. Washing of RBCs: Washing RBCs can remove some plasma proteins and antibodies, which may be helpful in preventing allergic reactions. However, it is not as effective as leukoreduction in preventing FNHTR, which is primarily caused by cytokines released from white blood cells.</li><li>\u2022 Option B. Washing of RBCs:</li><li>\u2022 Option D. Plasmapheresis of RBCs: Plasmapheresis is a procedure that separates plasma from blood cells and is not relevant to reducing the risk of FNHTR.</li><li>\u2022 Option D. Plasmapheresis of RBCs:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 UVB-treated RBCs may be considered as an alternative to leukoreduced RBCs in situations where leukoreduction is not feasible or unavailable. However, the efficacy of UVB treatment in preventing FNHTR is still under investigation.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b9fc309e",
      "audio": ""
    },
    {
      "text": "A 45-year-old male with a history of chronic kidney disease presents with fatigue and shortness of breath. His laboratory findings show a MCV 88 fL with a low reticulocyte production index (RPI < 2). Which of the following is the MOST likely cause of his anemia?",
      "options": [
        {
          "label": "A",
          "text": "Folate deficiency",
          "correct": false
        },
        {
          "label": "B",
          "text": "Iron deficiency anemia",
          "correct": false
        },
        {
          "label": "C",
          "text": "Hemolytic anemia",
          "correct": false
        },
        {
          "label": "D",
          "text": "Anemia of chronic disease",
          "correct": true
        }
      ],
      "correct_answer": "D. Anemia of chronic disease",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) Anemia of chronic disease</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Folate deficiency: Macrocytic anemia with high RPI.</li><li>\u2022 Option A. Folate deficiency:</li><li>\u2022 Option B. Iron deficiency anemia: Microcytic anemia with low RPI.</li><li>\u2022 Option B. Iron deficiency anemia:</li><li>\u2022 Option C. Hemolytic anemia: Normocytic/macrocytic anemia with high RPI.</li><li>\u2022 Option C. Hemolytic anemia:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Normocytic anemia with low RPI in the setting of chronic disease should prompt consideration of anemia of chronic disease.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "f3256155",
      "audio": ""
    },
    {
      "text": "A 55-year-old man with a history of rheumatoid arthritis presents with fatigue and a normocytic anemia (MCV 90 fL). His iron studies show the following: Serum iron: 30 mcg/dL (normal: 60-170 mcg/dL) TIBC: 200 mcg/dL (normal: 240-450 mcg/dL) Ferritin: 350 ng/mL (normal: 20-500 ng/mL) Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Anemia of chronic disease (ACD)",
          "correct": true
        },
        {
          "label": "B",
          "text": "Iron deficiency anemia (IDA)",
          "correct": false
        },
        {
          "label": "C",
          "text": "Thalassemia trait",
          "correct": false
        },
        {
          "label": "D",
          "text": "Sideroblastic anemia (SA)",
          "correct": false
        }
      ],
      "correct_answer": "A. Anemia of chronic disease (ACD)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. A) Anemia of chronic disease (ACD)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option B. Iron deficiency anemia (IDA): IDA would typically present with low serum iron, high TIBC, and low ferritin.</li><li>\u2022 Option B. Iron deficiency anemia (IDA):</li><li>\u2022 Option C. Thalassemia trait: This is a genetic condition causing microcytic anemia, not normocytic.</li><li>\u2022 Option C. Thalassemia trait:</li><li>\u2022 Option D. Sideroblastic anemia (SA): SA is less likely in this scenario as it often presents with elevated serum iron and ferritin.</li><li>\u2022 Option D. Sideroblastic anemia (SA):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Recognizing the distinct pattern of iron studies in anemia of chronic disease (low serum iron, low TIBC, and normal to elevated ferritin) is crucial for differentiating it from iron deficiency anemia. In the setting of a chronic inflammatory condition like rheumatoid arthritis, anemia of chronic disease is a common consideration.</li><li>\u2022 Recognizing the distinct pattern of iron studies in anemia of chronic disease (low serum iron, low TIBC, and normal to elevated ferritin) is crucial for differentiating it from iron deficiency anemia.</li><li>\u2022 In the setting of a chronic inflammatory condition like rheumatoid arthritis, anemia of chronic disease is a common consideration.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "9ed46f3a",
      "audio": ""
    },
    {
      "text": "A 32-year-old woman with heavy menstrual bleeding presents with fatigue and pallor. Her lab results show a microcytic anemia with an elevated red cell distribution width and a low reticulocyte count. Which of the following laboratory findings would MOST likely be seen in this patient?",
      "options": [
        {
          "label": "A",
          "text": "Normal serum iron, normal TIBC, and normal ferritin",
          "correct": false
        },
        {
          "label": "B",
          "text": "Low serum iron, high TIBC, and low ferritin",
          "correct": true
        },
        {
          "label": "C",
          "text": "Low serum iron, low TIBC, and high ferritin",
          "correct": false
        },
        {
          "label": "D",
          "text": "High serum iron, normal TIBC, and high ferritin",
          "correct": false
        }
      ],
      "correct_answer": "B. Low serum iron, high TIBC, and low ferritin",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Low serum iron, high TIBC, and low ferritin</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "ea582abf",
      "audio": ""
    },
    {
      "text": "A 28-year-old woman of Mediterranean descent is found to have mild microcytic anemia on routine blood work. Her iron studies are normal, and hemoglobin electrophoresis reveals an elevated HbA2 level. Which of the following is the most likely diagnosis?",
      "options": [
        {
          "label": "A",
          "text": "Iron deficiency anemia",
          "correct": false
        },
        {
          "label": "B",
          "text": "Anemia of chronic disease",
          "correct": false
        },
        {
          "label": "C",
          "text": "Beta-thalassemia trait",
          "correct": true
        },
        {
          "label": "D",
          "text": "Alpha-thalassemia trait",
          "correct": false
        }
      ],
      "correct_answer": "C. Beta-thalassemia trait",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Beta-thalassemia trait</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Iron deficiency anemia (IDA): While IDA is the most common cause of microcytic anemia, it would typically present with abnormal iron studies (low serum iron, low ferritin, and high total iron-binding capacity).</li><li>\u2022 Option A. Iron deficiency anemia (IDA):</li><li>\u2022 Option B. Anemia of chronic disease (ACD): ACD is typically normocytic, but can occasionally be microcytic. However, it would not typically cause elevated HbA2 levels on electrophoresis.</li><li>\u2022 Option B. Anemia of chronic disease (ACD):</li><li>\u2022 Option D. Alpha-thalassemia trait: Alpha thalassemia is another inherited disorder that can cause microcytic anemia, but it would not typically cause elevated HbA2 levels. Instead, it may be associated with an elevated HbH level or a normal hemoglobin electrophoresis.</li><li>\u2022 Option D. Alpha-thalassemia trait:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Beta-thalassemia is a common cause of microcytic anemia in individuals of Mediterranean descent. Hemoglobin electrophoresis is essential for diagnosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "dc4f97a2",
      "audio": ""
    },
    {
      "text": "A 25-year-old woman presents with a history of recurrent bacterial infections and is found to have low IgG levels. Which of the following is the most appropriate treatment option for her condition?",
      "options": [
        {
          "label": "A",
          "text": "Plasmapheresis",
          "correct": false
        },
        {
          "label": "B",
          "text": "Corticosteroids",
          "correct": false
        },
        {
          "label": "C",
          "text": "Intravenous immunoglobulin (IVIG)",
          "correct": true
        },
        {
          "label": "D",
          "text": "Rituximab",
          "correct": false
        }
      ],
      "correct_answer": "C. Intravenous immunoglobulin (IVIG)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) Intravenous immunoglobulin (IVIG)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Plasmapheresis: This is used to remove harmful substances from blood and is not indicated in this case.</li><li>\u2022 Option A. Plasmapheresis:</li><li>\u2022 Option B. Corticosteroids: While corticosteroids have immunomodulatory effects, they are not the first-line treatment for hypogammaglobulinemia.</li><li>\u2022 Option B. Corticosteroids:</li><li>\u2022 Option D. Rituximab: This is a monoclonal antibody targeting CD20-positive B cells and is not indicated for primary immunodeficiency.</li><li>\u2022 Option D. Rituximab:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 IVIG is a crucial therapy for patients with primary immunodeficiencies, providing passive immunity by supplementing IgG levels.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "b5e5da7f",
      "audio": ""
    },
    {
      "text": "Which of the following statements about myelodysplastic syndromes (MDS) is FALSE?",
      "options": [
        {
          "label": "A",
          "text": "MDS is a clonal hematopoietic stem cell disorder.",
          "correct": false
        },
        {
          "label": "B",
          "text": "Most patients with MDS will eventually progress to acute myeloid leukemia (AML).",
          "correct": true
        },
        {
          "label": "C",
          "text": "The risk of transformation to AML is higher in patients with complex karyotype abnormalities.",
          "correct": false
        },
        {
          "label": "D",
          "text": "Allogeneic stem cell transplantation is the only curative option for MDS.",
          "correct": false
        }
      ],
      "correct_answer": "B. Most patients with MDS will eventually progress to acute myeloid leukemia (AML).",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Most patients with MDS will eventually progress to acute myeloid leukemia (AML).</strong></p>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "967c7b58",
      "audio": ""
    },
    {
      "text": "A 65-year-old male presents with fatigue, weakness, and easy bruising. Peripheral blood smear shows macrocytic anemia and dysplastic neutrophils. Cytogenetic analysis reveals a deletion in the long arm of chromosome 5 (del(5q)). According to the IPSS-R, what is the patient's prognostic risk category?",
      "options": [
        {
          "label": "A",
          "text": "Very low",
          "correct": false
        },
        {
          "label": "B",
          "text": "Low",
          "correct": true
        },
        {
          "label": "C",
          "text": "Intermediate",
          "correct": false
        },
        {
          "label": "D",
          "text": "High",
          "correct": false
        }
      ],
      "correct_answer": "B. Low",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) Low</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. Very Low: While del(5q) MDS is a lower-risk subtype, it doesn't fall into the \"very low\" category, which is usually reserved for patients with very few cytopenias and no cytogenetic abnormalities.</li><li>\u2022 Option A. Very Low:</li><li>\u2022 Option C. Intermediate: This category typically includes patients with more cytopenias or less favorable cytogenetic findings than those with isolated del(5q).</li><li>\u2022 Option C. Intermediate:</li><li>\u2022 Option D. High: These categories are reserved for MDS with a high risk of progression to acute myeloid leukemia (AML), which is not typical of isolated del(5q). These patients usually have excess blasts in the bone marrow, complex karyotypes, or specific genetic mutations associated with worse outcomes.</li><li>\u2022 Option D. High:</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Del(5q) is a favorable cytogenetic abnormality in MDS associated with a better prognosis.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "bc69ed78",
      "audio": ""
    },
    {
      "text": "A 45-year-old man presents with fatigue, weight loss, and abdominal fullness. Physical examination reveals splenomegaly. Peripheral blood smear shows a leukocytosis with left shift. Which of the following genetic abnormalities is most likely to be found in this patient?",
      "options": [
        {
          "label": "A",
          "text": "JAK2 V617F",
          "correct": false
        },
        {
          "label": "B",
          "text": "BCR-ABL1",
          "correct": true
        },
        {
          "label": "C",
          "text": "FLT3-ITD",
          "correct": false
        },
        {
          "label": "D",
          "text": "t(15;17)",
          "correct": false
        }
      ],
      "correct_answer": "B. BCR-ABL1",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. B) BCR-ABL1</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. JAK2 V617F : Associated with myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF).</li><li>\u2022 Option A. JAK2 V617F</li><li>\u2022 Option C. FLT3-ITD : More commonly associated with acute myeloid leukemia (AML).</li><li>\u2022 Option C. FLT3-ITD</li><li>\u2022 Option D. t(15;17) : Associated with acute promyelocytic leukemia (APL), a subtype of AML.</li><li>\u2022 Option D. t(15;17)</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 BCR-ABL1 fusion gene is the diagnostic hallmark of CML.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "408c6fc9",
      "audio": ""
    },
    {
      "text": "What is the diagnostic hallmark of chronic myeloid leukemia (CML)?",
      "options": [
        {
          "label": "A",
          "text": "JAK2 V617F mutation",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(15;17) translocation",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(9;22) translocation (Philadelphia chromosome)",
          "correct": true
        },
        {
          "label": "D",
          "text": "t(8;21) translocation",
          "correct": false
        }
      ],
      "correct_answer": "C. t(9;22) translocation (Philadelphia chromosome)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. C) t(9;22) translocation (Philadelphia chromosome)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. JAK2 V617F mutation : This mutation is associated with myeloproliferative neoplasms (MPNs), not CML.</li><li>\u2022 Option A. JAK2 V617F mutation</li><li>\u2022 Option B. t(15;17) translocation : This translocation is the hallmark of acute promyelocytic leukemia (APL).</li><li>\u2022 Option B. t(15;17) translocation</li><li>\u2022 Option D. t(8;21) translocation : This translocation is associated with acute myeloid leukemia (AML).</li><li>\u2022 Option D. t(8;21) translocation</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 The Philadelphia chromosome is the defining genetic feature of CML.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "7b17debe",
      "audio": ""
    },
    {
      "text": "Which of the following cytogenetic abnormalities is associated with a high risk of relapse in AML?",
      "options": [
        {
          "label": "A",
          "text": "inv(16)",
          "correct": false
        },
        {
          "label": "B",
          "text": "t(15;17)",
          "correct": false
        },
        {
          "label": "C",
          "text": "t(8;21)",
          "correct": false
        },
        {
          "label": "D",
          "text": "-5/del(5q)",
          "correct": true
        }
      ],
      "correct_answer": "D. -5/del(5q)",
      "question_images": [],
      "explanation_images": [],
      "explanation": "<p><strong>Ans. D) -5/del(5q)</strong></p>\n<p><strong>Explanation:</strong></p><ul><li>\u2022 Explanation</li><li>\u2022 :</li><li>\u2022 Option A. inv(16): This inversion is associated with acute myeloid leukemia with abnormal eosinophils (AML M4Eo) and generally has a favorable prognosis.</li><li>\u2022 Option A. inv(16):</li><li>\u2022 Option B. t(15;17): This translocation is the hallmark of acute promyelocytic leukemia (APL), a subtype of AML. APL has a good prognosis when treated promptly with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO).</li><li>\u2022 Option B. t(15;17):</li><li>\u2022 Option C. t(8;21): This translocation is associated with acute myeloid leukemia with maturation (AML M2) and also has a relatively favorable prognosis.</li><li>\u2022 Option C. t(8;21):</li><li>\u2022 Educational objective :</li><li>\u2022 Educational objective</li><li>\u2022 :</li><li>\u2022 Cytogenetic abnormalities can significantly impact prognosis and treatment choices in AML.</li></ul>\n<p></p>",
      "bot": "@dams_new_robot",
      "video": "",
      "uid": "17ee4246",
      "audio": ""
    }
  ]
}